{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:09:23Z","timestamp":1791428963008,"version":"4.3.3"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Prescribing cascades are an underrecognized driver of polypharmacy among older adults (aged \u226565 years). The clinical decision-making processes underlying cascades and their downstream consequences are poorly understood.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To explore clinical reasoning leading to prescribing cascades and downstream outcomes (eg, falls, electrolyte abnormalities) via the exemplar gabapentinoid (gabapentin and pregabalin)\u2013loop diuretic (LD) cascade.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study randomly selected medical records from a cohort of US veterans aged 66 years or older between January 1, 2013, and August 31, 2019, who potentially experienced the gabapentinoid-LD prescribing cascade. The medical record review and data analysis were performed between October 24, 2023, and July 22, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Initiation of gabapentinoid and LD.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Abstractors evaluated clinical documentation in the 30 days prior to and 60 days after LD initiation to evaluate decision-making processes and potential downstream outcomes of the gabapentinoid-LD cascade. Secondary analyses examined whether a dementia diagnosis was associated with clinician decision-making and patient outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The analytic cohort comprised 120 patients (mean [SD] age, 73.9 [7.1] years; 116 male [96.7%]; 106 [88.3%] taking \u22655 long-term medications). Documentation of a differential diagnosis for edema was noted in 73 patients (60.8%), most commonly referencing congestive heart failure (n\u2009=\u200947 [39.2%]) and\/or venous stasis (n\u2009=\u200916 [13.3%]). Gabapentinoids were rarely noted in the differential (n\u2009=\u20094 [3.3%]). The majority of clinicians documented the indication for LD (n\u2009=\u2009116 [96.7%]), most commonly for lower-extremity edema (n\u2009=\u2009104 [86.7%]), congestive heart failure (n\u2009=\u200916 [13.3%]), and\/or dyspnea (n\u2009=\u200915 [12.5%]). In the 60 days following LD initiation, 28 patients (23.3%) experienced 37 events potentially attributable to LD initiation. The most common downstream events were worsening kidney function (n\u2009=\u20099 [7.5%]), orthostasis (n\u2009=\u20097 [5.8%]), electrolyte abnormalities (n\u2009=\u20096 [5.0%]), and falls (n\u2009=\u20095 [4.2%]). Six patients (5.0%) were evaluated in the emergency department and\/or hospital for potential downstream events. Documentation of differential diagnoses, indications, actions taken regarding gabapentinoids, and downstream events generally did not vary between patients with and without dementia.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found that among older veterans who received LD following gabapentinoid initiation and experienced a potential gabapentinoid-LD prescribing cascade, clinicians almost never explicitly considered gabapentinoid adverse drug effects in their treatment of edema. These findings suggest that potential downstream harms of this overlooked prescribing cascade are common, underscoring the importance of addressing prescribing cascades in clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.45274","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:00:16Z","timestamp":1764691216000},"page":"e2545274","source":"Crossref","is-referenced-by-count":2,"title":["Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade"],"prefix":"10.1001","volume":"8","author":[{"given":"Matthew E.","family":"Growdon","sequence":"first","affiliation":[{"name":"Division of Geriatrics, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Tjota","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Campbell","sequence":"additional","affiliation":[{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Gayda","sequence":"additional","affiliation":[{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bocheng","family":"Jing","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. James","family":"Deardorff","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute for Better Health, Trillium Health Partners, Mississauga, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Boockvar","sequence":"additional","affiliation":[{"name":"Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham"},{"name":"Geriatrics Research, Education, and Clinical Center, Birmingham VA Health Care System, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Steinman","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, University of California, San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"11","key":"zoi251222r1","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1111\/jgs.15543","article-title":"What is known about preventing, detecting, and reversing prescribing cascades: a scoping review.","volume":"66","author":"Brath","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"zoi251222r2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40266-022-00964-9","article-title":"ThinkCascades: a tool for identifying clinically important prescribing cascades affecting older people.","volume":"39","author":"McCarthy","year":"2022","journal-title":"Drugs Aging"},{"issue":"12","key":"zoi251222r3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40266-023-01072-y","article-title":"Prescribing cascades with recommendations to prevent or reverse them: a systematic review.","volume":"40","author":"Adrien","year":"2023","journal-title":"Drugs Aging"},{"key":"zoi251222r4","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1147921","article-title":"Research on prescribing cascades: a scoping review.","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"issue":"5","key":"zoi251222r5","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1008","article-title":"Prescribing cascades in community-dwelling adults: a systematic review.","volume":"10","author":"Doherty","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"zoi251222r6","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1111\/jgs.19191","article-title":"Identifying and quantifying potentially problematic prescribing cascades in clinical practice: a mixed-methods study.","volume":"72","author":"Mohammad","year":"2024","journal-title":"J Am Geriatr Soc"},{"issue":"8966","key":"zoi251222r7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0140-6736(95)92656-9","article-title":"Drug therapy.","volume":"346","author":"Rochon","year":"1995","journal-title":"Lancet"},{"issue":"5","key":"zoi251222r8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jgs.15800","article-title":"Assessing the scope and appropriateness of prescribing cascades.","volume":"67","author":"McCarthy","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"zoi251222r9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12877-020-01774-7","article-title":"Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study.","volume":"20","author":"Farrell","year":"2020","journal-title":"BMC Geriatr"},{"issue":"8","key":"zoi251222r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272418","article-title":"\u201cKind of blurry\u201d: deciphering clues to prevent, investigate and manage prescribing cascades.","volume":"17","author":"Farrell","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"zoi251222r11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s43058-024-00673-x","article-title":"A-I-D for cascades: an application of the Behaviour Change Wheel to design a theory-based intervention for addressing prescribing cascades in primary care.","volume":"5","author":"McCarthy","year":"2024","journal-title":"Implement Sci Commun"},{"issue":"7","key":"zoi251222r12","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac138","article-title":"Prescribing cascades: we see only what we look for, we look for only what we know.","volume":"51","author":"O\u2019Mahony","year":"2022","journal-title":"Age Ageing"},{"issue":"6","key":"zoi251222r13","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/jgs.18892","article-title":"Which older adults are at highest risk of prescribing cascades? a national study of the gabapentinoid-loop diuretic cascade.","volume":"72","author":"Growdon","year":"2024","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"zoi251222r14","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1111\/bcp.15447","article-title":"Association between gabapentinoids and oedema treated with loop diuretics: a pooled sequence symmetry analysis from the USA and Denmark.","volume":"88","author":"Vouri","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"zoi251222r15","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1111\/jgs.17312","article-title":"Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain.","volume":"69","author":"Read","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"zoi251222r16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.amjopharm.2004.09.004","article-title":"Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.","volume":"2","author":"Parsons","year":"2004","journal-title":"Am J Geriatr Pharmacother"},{"key":"zoi251222r17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2296-11-85","article-title":"Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies.","volume":"11","author":"Semel","year":"2010","journal-title":"BMC Fam Pract"},{"issue":"6","key":"zoi251222r18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults.","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi251222r19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/papr.12146","article-title":"A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain.","volume":"15","author":"Freynhagen","year":"2015","journal-title":"Pain Pract"},{"key":"zoi251222r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112807","article-title":"Gabapentinoid-induced peripheral edema and acute heart failure: a translational study combining pharmacovigilance data and in vitro animal experiments.","volume":"149","author":"Largeau","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"zoi251222r21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.9740\/mhc.2020.07.250","article-title":"Gabapentin-induced bilateral lower extremity edema in a patient with pervasive developmental disorder and schizoaffective disorder.","volume":"10","author":"Finegan","year":"2020","journal-title":"Ment Health Clin"},{"issue":"1","key":"zoi251222r22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jep.12223","article-title":"Evidence, regulation and \u2018rational\u2019 prescribing: the case of gabapentin for neuropathic pain.","volume":"21","author":"Ghinea","year":"2015","journal-title":"J Eval Clin Pract"},{"issue":"9","key":"zoi251222r23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","article-title":"Diuretic-related side effects: development and treatment.","volume":"6","author":"Sica","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"zoi251222r24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs.","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi251222r25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70149","article-title":"Trends in opioid and gabapentinoid utilization: a time-series analysis across 72 countries from 2012 to 2023.","volume":"34","author":"Liu","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi251222r26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jamda.2022.01.083","article-title":"Prevalence and risk factors for drug-related problems in people with dementia living in the community: a systematic review and meta-analysis.","volume":"23","author":"Lau","year":"2022","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"zoi251222r27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/1574884710666150812141525","article-title":"Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review.","volume":"10","author":"Elliott","year":"2015","journal-title":"Curr Clin Pharmacol"},{"issue":"9","key":"zoi251222r28","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1111\/jgs.17291","article-title":"Polypharmacy among older adults with dementia compared with those without dementia in the United States.","volume":"69","author":"Growdon","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"zoi251222r30","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1037\/h0031619","article-title":"Measuring nominal scale agreement among many raters.","volume":"76","author":"Fleiss","year":"1971","journal-title":"Psychol Bull"},{"issue":"1","key":"zoi251222r31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/pds.5362","article-title":"Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: loop diuretic prescribing cascade.","volume":"31","author":"Vouri","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi251222r32","first-page":"13","article-title":"Prescribing cascade. a proposed new way to evaluate it.","volume":"77","author":"Ponte","year":"2017","journal-title":"Medicina (B Aires)"},{"issue":"12","key":"zoi251222r33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.18425","article-title":"Magnitude of and characteristics associated with the treatment of calcium channel blocker-induced lower-extremity edema with loop diuretics.","volume":"2","author":"Vouri","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi251222r34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamainternmed.2019.7087","article-title":"Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension.","volume":"180","author":"Savage","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi251222r35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s11606-021-06611-0","article-title":"Measuring and improving diagnostic safety in primary care: addressing the \u201ctwin\u201d pandemics of diagnostic error and clinician burnout.","volume":"36","author":"Olson","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"5","key":"zoi251222r36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jamainternmed.2019.7082","article-title":"Antihypertensive prescribing cascades as high-priority targets for deprescribing.","volume":"180","author":"Anderson","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi251222r37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40266-023-01091-9","article-title":"Evaluating provider and pharmacy discordance in potential calcium channel blocker-loop diuretic prescribing cascade.","volume":"41","author":"Ndai","year":"2024","journal-title":"Drugs Aging"},{"issue":"7","key":"zoi251222r38","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40266-021-00868-0","article-title":"Differences in health-related quality of life among adults with a potential dihydropyridine calcium channel blocker-loop diuretic prescribing cascade.","volume":"38","author":"Morris","year":"2021","journal-title":"Drugs Aging"},{"issue":"2","key":"zoi251222r39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jgs.18683","article-title":"Association of a calcium channel blocker and diuretic prescribing cascade with adverse events: a population-based cohort study.","volume":"72","author":"Rochon","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"zoi251222r40","doi-asserted-by":"publisher","first-page":"m261","DOI":"10.1136\/bmj.m261","article-title":"Using a clinical process map to identify prescribing cascades in your patient.","volume":"368","author":"Piggott","year":"2020","journal-title":"BMJ"},{"issue":"10","key":"zoi251222r41","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40266-024-01148-3","article-title":"Prevalence of adverse drug reactions in hospital among older patients with and without dementia.","volume":"41","author":"Sakiris","year":"2024","journal-title":"Drugs Aging"},{"key":"zoi251222r42","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620968310","article-title":"Prescribing cascades in persons with Alzheimer\u2019s disease: engaging patients, caregivers, and providers in a qualitative evaluation of print educational materials.","author":"Bloomstone","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"zoi251222r43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.9679","article-title":"Measurement of fall injury with health care system data and assessment of inclusiveness and validity of measurement models.","volume":"2","author":"Min","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi251222r44","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/j.1532-5415.2011.03500.x","article-title":"Beyond the prescription: medication monitoring and adverse drug events in older adults.","volume":"59","author":"Steinman","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"zoi251222r45","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","article-title":"Adverse drug reactions in special populations - the elderly.","volume":"80","author":"Davies","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"zoi251222r29","unstructured":"The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. World Health Organization. Accessed April 11, 2025. https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2842165\/growdon_2025_oi_251222_1763745950.32437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T16:00:19Z","timestamp":1764691219000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2842165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.45274","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]}}}